Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
Eline Elshof
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
Saskia V Vijver
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
Jahangheer Shaik
NextCure, Beltsville, United States
Jason Bosiacki
NextCure, Beltsville, United States
Zachary Cusumano
NextCure, Beltsville, United States
Christina Jensen
Nordic Bioscience, Herlev, Denmark
Nicholas Willumsen
Nordic Bioscience, Herlev, Denmark
Morten A Karsdal
Nordic Bioscience, Herlev, Denmark
Linda Liu
NextCure, Beltsville, United States
Sol Langermann
NextCure, Beltsville, United States
Stefan Willems
Department of Pathology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands
Center for Translational Immunology, University Medical Center Utrecht, Utrecht University, Utrecht, Netherlands; Oncode Institute, Utrecht, Netherlands
Collagens are a primary component of the extracellular matrix and are functional ligands for the inhibitory immune receptor leukocyte-associated immunoglobulin-like receptor (LAIR)-1. LAIR-2 is a secreted protein that can act as a decoy receptor by binding collagen with higher affinity than LAIR-1. We propose that collagens promote immune evasion by interacting with LAIR-1 expressed on immune cells, and that LAIR-2 releases LAIR-1-mediated immune suppression. Analysis of public human datasets shows that collagens, LAIR-1 and LAIR-2 have unique and overlapping associations with survival in certain tumors. We designed a dimeric LAIR-2 with a functional IgG1 Fc tail, NC410, and showed that NC410 increases human T cell expansion and effector function in vivo in a mouse xenogeneic-graft versus-host disease model. In humanized mouse tumor models, NC410 reduces tumor growth that is dependent on T cells. Immunohistochemical analysis of human tumors shows that NC410 binds to collagen-rich areas where LAIR-1+ immune cells are localized. Our findings show that NC410 might be a novel strategy for cancer immunotherapy for immune-excluded tumors.